Taken together, our results demonstrate SMYD2 is involved into cisplatin resistance through regulating p53 pathway, and might become a promising therapeutic target for cisplatin resistance in NSCLC. The gene discussed is SMYD2; the disease is non-small cell lung carcinoma.